Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
Personalis to Announce First Quarter 2024 Financial Results
04:01pm, Wednesday, 24'th Apr 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday,
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
04:01pm, Thursday, 28'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 23rd Annual Needham Virtual He
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
09:00am, Thursday, 28'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for th
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced a new publication validating the company's NeXT Personal test,
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:43pm, Tuesday, 19'th Mar 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
09:20pm, Wednesday, 28'th Feb 2024
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Wednesday, 14'th Feb 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full year 2023 financial result
Personalis to Participate at Upcoming Investor Conferences
04:01pm, Wednesday, 31'st Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the following investor confere
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
09:00am, Tuesday, 30'th Jan 2024
FREMONT, Calif. & SAN DIEGO--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveile
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 17'th Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
09:05am, Tuesday, 16'th Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced it has received a final Medicare coverage determination for its
Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
09:05am, Friday, 05'th Jan 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full ye
Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
09:15am, Monday, 04'th Dec 2023
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company's
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
04:15pm, Tuesday, 28'th Nov 2023
FREMONT, Calif. & CHICAGO--(BUSINESS WIRE)--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precis
Personalis, Inc. (PSNL) Q3 2023 Earnings Call Transcript
11:04pm, Tuesday, 07'th Nov 2023
Personalis, Inc. (NASDAQ:PSNL ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich
